OQROGet OQRO Pro
Insider trade

Regeneron Pharmaceuticals (REGN)Director sold ~$11K

Arthur F Ryan, Director at Regeneron Pharmaceuticals, sold ~$11K of Regeneron Pharmaceuticals shares.

~$11K
Approx. value · 15 sh @ $702.46
18K
Holds after · shares reported
Traded
May 1, 2026
Filed
May 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Feb 12, 2026CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
  2. Mar 2, 2026Insider · 1 personInsiders: 13 sales (~$79K)
  3. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  4. Mar 27, 2026CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
  5. Apr 1, 2026Insider · 1 personInsiders: 9 sales (~$78K)
  6. Apr 2, 2026FDAFDA drug approval: Eylea HD
  7. Apr 8, 2026Company filing · Form 8-K · ResultsReported its results
  8. Apr 22, 2026FDAFDA drug approval: Dupixent
  9. Apr 29, 2026Company filing · Form 8-K · ResultsReported its results
  10. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.4%
  11. May 1, 2026 · this disclosureInsiderDirector sold ~$11K of REGN shares in the open market

What came next

  1. May 1, 2026Insider · 1 personInsiders: 11 sales (~$60K)
  2. May 6, 2026Government · Federal Register noticeIssuance of Priority Review Voucher; Rare Pediatric Disease Product; OTARMENI (lunsotogene parvec-cwha)
  3. May 15, 2026CongressDisclosed sale of REGN — reported range $1,001 - $15,000
  4. Jul 2, 2026InsiderDirector sold ~$130K of REGN shares in the open market
  5. Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
  6. Jul 16, 2026Court · District Court, S.D. New YorkSecurities lawsuit filed: Cheatham v. Regeneron Pharmaceuticals, Inc.
  7. Jul 28, 2026FDARecall: Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pha…
  8. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
  9. Aug 10, 2026Insider · 2 peopleInsiders: 2 sales (~$960K)
  10. Aug 19, 2026FDAFDA drug approval: Pasatru
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Regeneron Pharmaceuticals

For Regeneron Pharmaceuticals, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 31 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.

Other recent filings by Arthur F Ryan, Director

The full history of Arthur F Ryan, Director is on the profile page.

How this filing works

Other disclosures at Regeneron Pharmaceuticals

Everything OQRO holds on this company is on its REGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data